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Abstract
Accurate diagnosis in suspected ischaemic stroke can be difficult. We explored the urinary proteome in patients with stroke
(n = 69), compared to controls (n = 33), and developed a biomarker model for the diagnosis of stroke. We performed
capillary electrophoresis online coupled to micro-time-of-flight mass spectrometry. Potentially disease-specific peptides
were identified and a classifier based on these was generated using support vector machine-based software. Candidate
biomarkers were sequenced by liquid chromatography-tandem mass spectrometry. We developed two biomarker-based
classifiers, employing 14 biomarkers (nominal p-value ,0.004) or 35 biomarkers (nominal p-value ,0.01). When tested on a
blinded test set of 47 independent samples, the classification factor was significantly different between groups; for the
35 biomarker model, median value of the classifier was 0.49 (20.30 to 1.25) in cases compared to 21.04 (IQR 21.86 to
20.09) in controls, p,0.001. The 35 biomarker classifier gave sensitivity of 56%, specificity was 93% and the AUC on ROC
analysis was 0.86. This study supports the potential for urinary proteomic biomarker models to assist with the diagnosis of
acute stroke in those with mild symptoms. We now plan to refine further and explore the clinical utility of such a test in
large prospective clinical trials.
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Introduction
Prompt and accurate diagnosis is crucial for the effective
management of ischaemic stroke and transient ischaemic attack
(TIA). Both are clinical diagnoses, supported by imaging findings.
Even when patients are assessed by a specialist in cerebrovascular
medicine, as many as one fifth of patients initially thought to have
a stroke [1], and one half of patients initially felt to have had a TIA
[2], eventually receive an alternate diagnosis.
Clinical assessment tools can facilitate accurate diagnosis and are
increasingly used in the routine evaluation of patients with suspected
stroke [2,3,4], yielding diagnostic accuracy in the range of 80–90%.
The use of brain imaging, particularly magnetic resonance imaging
(MRI), can provide further certainty and in the setting of stroke is
required to distinguish ischaemia from haemorrhage. In one study,
where MRI with diffusion weighted imaging (DW-MRI) was
directly compared to CT [5], sensitivity of MRI for the detection
of acute cerebral ischaemia was < 83%. Although this is vastly
superior to non-contrast CT in the detection of acute ischaemia
(sensitivity 16%), the false negative rate of MRI approximates to
17%, and it cannot be performed in all patients [5].
The ability rapidly to confirm the presence of stroke, particular
minor ischaemic stroke or TIA and in the significant number of
patients in whom there is early diagnostic doubt would be
advantageous [6,7]. One potential approach is the use of
proteomics, which involves the simultaneous analysis of thousands
of proteins and peptides. Changes in the expression of several
proteins have been described in brain extracellular fluid and plasma
of those with acute stroke [8,9]. Recently, urinary proteomic
biomarker models have been developed and showed potential for
accurate identification of those with, or at high risk of, cardiovas-
cular disorders such as ischaemic heart disease [10], diabetes,
diabetic nephropathy [11] and pre-eclampsia [12]. We hypothesised
that a urinary proteomic biomarker model could be developed to
reliably identify those with minor ischaemic stroke or TIA (those
most likely to have inconclusive brain imaging) and that biomarkers
would be discovered which were associated with stroke severity. We
developed such a biomarker model in a cohort of patients with minor
ischaemic stroke and a control population with excess cardiovascu-
lar risk but no history of recent stroke or TIA.
Results
Demographic Variables
Urine samples were available from 65 cases and 41 controls. All
samples available were included in the proteomics study. There
were differences between the case and control groups in baseline
characteristics (table 1). Cases had a lower frequency of
hypertension and use of alpha-blockers and calcium channel
blockers. However, all except one control and nine cases were
taking at least one anti-hypertensive drug. Of cases, 20 (31.3%)
suffered TIA, the remainder had suffered stroke and 40 (61.5%)
had findings compatible with cerebrovascular disease on brain
imaging although acute cerebral infarction was only demonstrated
in 10 (16.1%) cases. CT was the most commonly performed
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imaging modality. Partial anterior circulation stroke was the
commonest subtype.
Biomarkers for Presence of Stroke or TIA
All samples were analyzed with CE-MS, and processed to result
in an individual list of peptides and proteins present in each
sample, as well as normalized ion counts as measure for relative
abundance. To identify potential biomarkers for stroke, 26 control
samples and 33 cases were randomly selected. This left a second,
blinded test set, consisting of the remaining 47 samples. These
were analyzed under identical conditions. This approach has been
proven superior in the past to avoid bias introduced due to analysis
of training- and test-set under slightly different conditions.
The compiled proteomics data of the 26 control and 33 case
samples was used to identify potential biomarkers and also to
establish a classifier (the biomarker model). These data are shown
in figure 1. Only two biomarkers were identified that also passed
rigorous adjustment for multiple testing (table 2). Since
multidimensional classifier models based on only 2 biomarkers
perform poorly, we selected additional candidates. Two classifiers
based on either 14 potential biomarkers (all peptides in the dataset
with a nominal p-value ,0.004) or 35 potential biomarkers (all
peptides in the dataset with a nominal p-value ,0.01) were
established. The distribution of these 35 potential biomarkers is
shown in figure 2.
When tested on the blinded test set of 47 samples (32 cases,
15 controls), the proteomic signal was significantly different
between groups; in the 14 biomarker model, median value of
the classifier was 0.96 (21.04 to 3.3) in cases compared to 21.06
(IQR 23.18 to 0.35) in controls, p = 0.006; in the 35 biomarker
model, median value of the classifier was 0.49 (20.30 to 1.25) in
cases compared to 21.04 (IQR 21.86 to 20.09) in controls,
p,0.001. The 14 biomarker model had sensitivity of 75% and
specificity of 73% for identification of stroke and gave an area
under the curve (AUC) of 0.75 on ROC analysis. The 35
biomarker model performed better; sensitivity was 56%, specificity
was 93% and the AUC on ROC analysis was 0.86 (figure 3).
Peptide Sequences of Identified Biomarkers
We were able to sequence and identify several of the peptides
included in the biomarker models (on-line appendix). These
included FXYD domain-containing ion transport regulator 4,
inter-alpha-trypsin inhibitor heavy chain H4, uromodulin, poly-
meric-immunoglobulin receptor and collagen fragments.
Biomarkers Associated with Severity of Stroke
To identify potential biomarkers associated with severity of
stroke, all proteomic data from cases were included in the analysis.
A total of 4453 urinary proteins and peptides detected in the
samples were investigated for their correlation with the NIHSS
score. Several urinary peptides correlated with the NIHSS score,
although only at a moderately high level. Since only the data from
patients with stroke were examined, the correlated peptides
showed essentially no overlap with the potential diagnostic
peptides that differentiate between stroke and control; only one
peptide was identical in both sets. In an attempt to develop a
classifier that may enable classification of the patients with respect
to disease severity, several of the potential biomarkers were
combined using linear combination of the normalized amplitude
of the single biomarkers. Such linear combination generally does
not result in ‘‘overfitting’’, as it is one-dimensional only. When
subsequently testing the classifier based on the 34 potential
biomarkers that showed the highest correlation, it was strongly
correlated with NIHSS score (r = 0.74, 95% CI 0.60 to 0.84,
p =,0.0001) (figure 4).
Discussion
We explored the urinary proteome in patients with acute stroke
or TIA and in a group of controls with elevated cardiovascular
risk. We were able to identify a panel of potential urinary peptide
biomarkers, for two of these we could establish significant
differences in a small cohort of patients with acute stroke or TIA
in comparison to a control group. When combining several of
these potential biomarkers to an SVM-based classifier / biomarker
model, this classifier was associated with stroke with very high
significance, and enabled separating of a second blinded cohort
with good accuracy; an AUC of 0.86. These results indicate that
urinary biomarkers enable the detection of stroke in the
population at risk. As already demonstrated previously [10,13],
the data also clearly indicate that classifiers based on a larger
number of biomarkers enable higher accurate classification, are
significantly superior to single or only few biomarker-based
classifiers. This is in part owed to biological variability; while the
urinary peptides can generally be analyzed with high accuracy,
their level is to a substantial degree subject to biological variability,
which can be counteracted by combining an array of biomarker
peptides [14]. Further, we were able to identify a number of
peptides which correlated with stroke severity. Importantly, this
Table 1. Baseline Characteristics.
Variable Cases Controls P Value
Age, years 70.1 (10.6) 66.5 (11.2) 0.100
Female Sex 31 (47.7%) 17 (40.5%) 0.552
Stroke 44 (68.8%) – –
TIA 20 (31.3%) – –
Total Anterior Circulation Stroke 6 (9.4%) – –
Partial Anterior Circulation Stroke 30 (46.9%) – –
Lacunar Stroke 18 (28.1%) – –
Posterior Circulation
Stroke
1 (1.6%) – –
NIHSS Score (median, IQR) 2 (2–4) – –
Smoker 20 (30.8%) 6 (14.3%) 0.066
Ischaemic Heart Disease 20 (30.8%) 11 (26.2%) 0.667
Previous CVA 19 (29.2%) 0 ,0.001
PVD 2 (3.1%) 3 (7.1%) 0.379
Diabetes Mellitus 4 (6.2%) 8 (19.0%) 0.058
Hyperlipidaemia 14 (21.5%) 8 (19.0%) 0.811
Hypertension 34 (52.3%) 36 (85.7%) ,0.001
Atrial Fibrillation 6 (9.2%) 2 (4.8%) 0.477
Dipyridamole Therapy 13.8 (9%) 1 (2.4%) 0.085
ACE I or ARB Therapy 36 (55.4%) 22 (52.4%) 1
Diuretic Therapy 24 (36.9%) 22 (52.4%) 0.161
Beta-blocker Therapy 23 (35.4%) 20 (47.6%) 0.231
CCB Therapy 23 (33.8%) 23 (54.8%) 0.045
Alpha-blocker Therapy 2 (3.1%) 8 (19.0%) 0.013
Any Antihypertensive Therapy 56 (86%) 41 (98%) 0.085
Statin Therapy 50 (76.9%) 31 (73.8%) 1
For continuous variables, values given are mean (SD) unless stated.
doi:10.1371/journal.pone.0035879.t001
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was achieved in a cohort of patients with minor stroke and TIA.
When combing these biomarker to a linear classifier, very good
correlation with the NIHSS score could be obtained. Thus, as well
as assisting with diagnosis, our data suggest proteomic changes
related to severity of stroke which if confirmed could provide
mechanistic insights and help with risk stratification after
ischaemic stroke.
The diagnosis of stroke and TIA can be difficult. The use of
clinical scoring systems and brain imaging can enhance sensitivity
and diagnostic accuracy. CT imaging performs poorly in this
setting with reported sensitivity of 16% early after ischaemic stroke
[5] and we found similar in our study. Crucially, even with MRI
imaging, sensitivity does not reach 100%; even with use of
diffusion weighted MRI imaging meaning novel means to facilitate
diagnosis would be a tremendous advantage. Key predictors of
false-negative diffusion weighted imaging include a brainstem
location of stroke and lower NIHSS score [6]. In a further study,
25% of patients with mild stroke or stroke-like deficits had a
negative DWI study [7]. Thus, while MRI is the imaging modality
of choice, it has limitations; sensitivity is not 100%, particularly
after mild stroke or TIA and around 10% of patients are unable to
undergo MRI because of contraindications including electronic
implants, medical instability, agitation and claustrophobia. Fur-
ther, MRI is not always available and in many countries non-
contrast CT remains the initial imaging modality of choice. In our
study, mean NIHSS score was 3.1 suggesting our biomarker model
may enhance diagnostic certainty in exactly the group where even
diffusion weighted MRI is not definitive. This is the first study to
show that models based on the urinary proteomic signal have
potential to assist with the diagnosis of stroke. Although sensitivity
of our model was 54%, specificity was high and further studies will
aim to improve model performance.
We have developed a biomarker model using urine samples.
This would carry several advantages over a plasma based model.
First, the urinary proteome is more stable that than in plasma.
This raises the possibility of community based sampling, in cases of
suspected mild stroke in rural environments which is less feasible
for plasma proteome analysis. We found the biomarker model with
35 included biomarkers performed best, which is in line with
previous observations where classifiers based on a larger number
of biomarkers result in increased accuracy [10].
We were able to sequence a number of the peptides in the
biomarker models, several of which may have roles in the
pathophysiology of acute ischaemic stroke. For example, these
included one which has recently been shown by other groups to be
under-expressed in acute ischaemic stroke (inter-alpha-trypsin
inhibitor heavy chain H4) [15]. FXYD-4 (CHIF) is a regulator of
Na-K-ATPase [16]. Dysfunction of such ion pumps is a key
feature of the cytotoxic oedema which occurs in acute ischaemic
stroke and expression of FXYD-4 is altered in renal ischaemic
Figure 1. Urinary polypeptide signatures in cases and controls. Normalized molecular weight (800–20 000 Da) in logarithmic scale is plotted
against normalized migration time (18–45 minutes). The mean signal intensity of the polypeptide peak is given in 3-dimensional depiction. n = 26
controls and 33 cases.
doi:10.1371/journal.pone.0035879.g001
Figure 2. Polypeptide signatures of the 35 biomarker model in cases and controls. Normalized molecular weight (800–20 000 Da) in
logarithmic scale is plotted against normalized migration time (18–45 minutes). The mean signal intensity of the polypeptide peak is given in 3-
dimensional depiction. n = 26 controls and 33 cases.
doi:10.1371/journal.pone.0035879.g002
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injury [17]. Polymeric-immunoglobulin receptor is known to be
expressed in neuronal tissue and may be implicated in protein
transcytosis across the blood brain barrier [18]. Blood brain
barrier dysfunction is also a pathological feature of acute ischaemic
stroke. Phosphatases have been implicated in the pathogenesis of
other brain disorders [19] and gamma-glutamyl transpeptidase is
present on the apical surface of endothelial cells at the blood brain
barrier and expression increases in animal models of stroke [20].
An angiotensinogen peptide also differed between controls and
cases. There are several possible explanations for this. The renin –
angiotensin system is involved both in the pathogenesis of
hypertension, is modulated by numerous anti-hypertensive agents
but is also a critical mediator of ischaemic injury in acute stroke
[21]. Given the use of most anti-hypertensive drugs was similar
and hypertension was common in both groups, this difference may
well reflect the ischaemic injury in the case group. Uromodulin
levels were slightly lower in cases. There are recent reports that
uromodulin may have a role in blood pressure regulation and uric
acid metabolism [22], both of which link with outcome after
stroke. Further, uromodulin may induce inflammatory cytokine
production [23]. Several collagen fragments were predictive of
stroke. Whilst the exact biological function of collagen fragments is
unclear in acute stroke, it is unsurprising that collagen be affected
given its abundance in extracellular matrix of blood vessel
adventitia. Given that some collagen fragments were increased
in cases and others were reduced, it is possible that these changes
Table 2. Proteins included in biomarker models. Mass is measure in Daltons.
Mass
CE
time Protein Name Protein Sequence P value
896.5 22.5 Gamma-glutamyltranspeptidase 2 VAVPGEIRG ,0.001 *
1164.5 26.1 FXYD domain-containing ion transport regulator 4 DPFANKDDPF 0.005
1170.6 26.4 Beta-2-microglobulin SDLSFSKDWS 0.007
1170.6 21.2 Hemoglobin subunit alpha VLSPADKTNVK 0.009
1194.6 29.2 Collagen alpha-1(I) chain GDRGEpGPpGPAG ,0.001 *
1210.4 36.5 Protein Phosphatase 1 regulatory subunit 3F isoform 1 GGGEGSTDGGmSPS 0.009
1240.6 27.1 Inter-alpha-trypsin inhibitor heavy chain H4 FSVMPGLKMTM 0.007
1532.6 26.4 Collagen alpha-1(II) chain RDGEPGTPGNpGPpGP 0.003 *
1541.6 24.5 Fibrinogen alpha chain DEAGSEADHEGTHST ,0.001 *
1576.6 26.4 FRAS1-related extracellular matrix protein 3 RPSFMATmMmEVD 0.005
1640.6 23.2 – – 0.004
1640.7 31.0 Collagen alpha-3(IX) chain AAGAGLDGpEGDQGpQGp ,0.001 *
1773.82 34.6 Isoform 1 of Collagen alpha-1(IV) chain GppGPPGppGPPGEKGQMG ,0.001 *
1786.6 38.3 – – 0.003 *
1794.7 23.3 – – ,0.001
1911.1 25.0 Uromodulin SGSVIDQSRVLNLGPITR 0.005 *
1912.9 32.7 Collagen alpha-1 (I) chain NGApGNDGAKGDAGApGApGSQ 0.004 *
1925.8 23.2 Isoform 1 of Fibrinogen alpha chain PGSPRPGSTGTWNPGSSER 0.003 *
1949.9 21.7 Collagen alpha-1 (I) chain GDDGEAGKpGRpGERGPPGp 0.002
1952.9 32.2 Collagen alpha-2(I) chain GEKGpSGEAGTAGPpGTpGPQG 0.005
1956.1 33.0 Ceruloplasmin (ferroxidase) NGRQKDVDKEFYLFPT 0.005
2007.9 22.1 Collagen alpha-1 (III) chain DGESGRpGRpGERGLpGPpG 0.005
2168.6 35.1 – – 0.008
2548.3 35.2 AGT Angiotensinogen FAVYDQSATALHFLGRVANPLSTA 0.009 *
2607.2 34.4 Collagen alpha-1(XXVII) chain GSKGQpGDSGEMGFpGmAGLFGPKGPP 0.001
2682.1 22.5 – – 0.009
2791.3 29.5 – – 0.009
3157.1 34.7 – – 0.002 *
3223.4 39.1 – – 0.007
3292.5 39.4 – – ,0.001 *
3359.6 31.9 Collagen alpha-1 (I) chain PpGADGQPGAKGEpGDAGAKGDAGPpGPAGPAGPpGPIG 0.008
3583.6 41.5 – – 0.002 *
3681.5 23.5 – – 0.006
4218.0 26.1 Polymeric-immunoglobulin receptor EEKAVADTRDQADGSRASVDSGSSEEQGGSSRALVSTLVPLG 0.006
4263.0 23.5 – – 0.010
CE-time = capillary electrophoresis migration time. All proteins were included in the M35p001 model. * = included in the M14 sig model. The 2 biomarkers that passed
adjustment for multiple testing are labeled in bold.
doi:10.1371/journal.pone.0035879.t002
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reflect levels of an as yet unidentified protease. Our biomarker
models are therefore based on peptides with clear biologic
plausibility and provide potential mechanistic insights worthy of
further evaluation.
There are weaknesses to consider. This study is not a
comparison of the urinary proteome between those presenting
with suspected stroke who have stroke mimic with those who have
confirmed stroke. However, rather than a healthy control group,
our control group was recruited from cardiovascular risk factor
clinics and most had hypertension and a substantial number had
established ischaemic heart disease. The ability of the biomarker
model to distinguish those with stroke from non-stroke patients at
high cardiovascular risk suggests that it may perform well when
tested in those with stroke mimic. Participants were originally
recruited to a study of aspirin resistance which makes generaliza-
tion of our results an important consideration. However, since
inclusion and exclusion criteria were wide, with the exception of
the requirement for pre-existing aspirin use, we believe our results
are generalizable.
There were some differences between the case and control
groups. Cases had a higher incidence of previous stroke, and lower
incidence of hypertension and lower usage of calcium channel
blockers. It is possible, but unlikely, that these differences will have
confounded results. A substantial minority of our cases had
suffered TIA; albeit a TIA deemed severe enough to warrant
admission to hospital. The proteomic signal in those with NIHSS
of 0 was similar to that in controls suggesting that our model may
perform best in those with minor stroke (where it would still be
clinically useful) rather than in those with suspected TIA. We
found a correlation between 34 biomarkers and NIHSS score but
this was a mild cohort of stroke patients and this finding needs to
be replicated in a wider population of stroke patients.
Our study was small, but it enabled identification of biomarkers
and the generation of classifiers that also were validated in
independent blinded samples, following recommended procedures
for proteomic analysis [24]. While the data show a clear and
highly significant association of the biomarkers and models with
stroke, it is evident that the results require further refinement and
evaluation in larger prospective studies where we can fully assess
the potential role in clinical practice.
In summary, we have developed a urinary proteomic biomarker
model which shows potential to assist with the diagnosis of acute
stroke in those with mild symptoms, and in the assessment of
severity. We now plan to explore the clinical utility of such a test in
large prospective clinical trials.
Figure 3. Receiver operating characteristics curve for the 14 and 35 biomarker models.
doi:10.1371/journal.pone.0035879.g003
Figure 4. Scatter plot of National Institute of Health of Stroke
Scale (NIHSS) score and the biomarker model classifier (modA).
doi:10.1371/journal.pone.0035879.g004
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Materials and Methods
Study Population
The study was performed in the Institute of Cardiovascular and
Medical Sciences at the University of Glasgow. The study protocol
was approved by the Scottish Multicenter Research Ethics
Committee A. All participants gave written informed consent
before participation in the study. Samples were obtained during a
study of the prevalence of aspirin resistance in those with acute
stroke [25]. In this study, all participants gave blood samples for
platelet function analysis and a proportion gave their first urine
sample following admission.
Cases were aged .18 years, were taking aspirin therapy, and
had a diagnosis of ischaemic stroke or transient ischaemic attack.
All participants were recruited within 24 hours of onset of
symptoms and the first urine passed thereafter was used. Urine
samples were thus all obtained within 24 hours (median time from
recruitment to obtaining urine sample 20 minutes, IQR 0 to
60 minutes) and before further drug treatment was used. Those
with brain imaging which suggested intracerebral haemorrhage
were excluded. Cases were identified on admission to the Acute
Stroke Unit and gave informed consent. Where potential
participants were unable to consent, assent from the nearest
relative or welfare guardian was accepted. Consecutive patients
meeting these criteria were included. We followed our well
established procedures for identifying those who have suffered
stroke or TIA. All participants referred to our unit are reviewed
within 24 hours of first contact by a Consultant Stroke Physician
and standard investigations organized. Clinical features, imaging
findings and diagnosis is then reviewed in a multi-disciplinary
team meeting which includes 6 Consultant Stroke Physicians, a
Radiologist and a Neurologist. It is at this meeting that a final
consensus diagnosis of stroke or non-stroke is applied.
Controls comprised individuals aged over 18 years of age who
were taking aspirin therapy. They were required to be at excess
cardiovascular risk, defined as attending a secondary care specialist
cardiovascular risk factor clinic. They were required to have taken
aspirin for a minimum of one year, to never to have suffered a
cardiovascular event on aspirin and to never have suffered stroke
or stroke like symptoms. Exclusion criteria were the same as for
cases (with the exception of the need for brain imaging). All gave
informed consent and were mostly identified during out-patient
attendance at local out-patient clinics.
All urine samples were immediately frozen at 270uC.
Sample preparation
Sample preparation was performed as described previously
[26]. In short, a 0.7 mL aliquot was thawed immediately before
use and diluted with 0.7 mL 2 M urea, 10 mM NH4OH
containing 0.02% SDS. To remove proteins of higher molecular
mass the sample was filtered using a Centrisart ultracentrifugation
filter device (20 kDa MW cut-off; Sartorius, Goettingen, Ger-
many) at 3,000 rcf until 1.1 ml filtrate was obtained. The filtrate
was then loaded onto a PD-10 desalting column (GE Healthcare,
Sweden) and equilibrated in 0.01% NH4OH in HPLC-grade
H2O (Roth, Germany) to decrease matrix effects by removing
urea, electrolytes, and salts, and also to enrich polypeptides.
Finally, samples were lyophilized and stored at 4uC. Shortly before
CE-MS analysis, lyophilisates were resuspended in HPLC-grade
H20 to a final protein concentration of 0.8 mg/mL verified by the
BCA test (Interchim, Montlucon, France).
Capillary Electrophoresis-Mass Spectometry (CE-MS)
analysis
All samples available were analysed with CE-MS in accordance
with recently published guidelines for clinical proteome analysis
[24]. CE-MS analysis was performed as previously described using a
P/ACE MDQ capillary electrophoresis system (Beckman Coulter,
Fullerton, USA) on-line coupled to a MicroTOF MS (Bruker
Daltonic, Bremen, Germany) [12]. The ESI sprayer (Agilent
Technologies, Palo Alto, USA) was grounded, and the ion spray
interface potential was set between 24.0 and 24.5 kV. Data
acquisition and MS acquisition methods were automatically
controlled by the CE via contact-close-relays. Spectra were
accumulated every 3 s over a range of m/z 350 to 3000. Details
on accuracy, precision, selectivity, sensitivity, reproducibility, and
stability of the CE-MS method have been provided previously
[26,27].
Data processing
Mass spectral ion peaks representing identical molecules at
different charge states were deconvoluted into single masses using
MosaiquesVisu software [28]. Only those signals with z .1 that
were observed in a minimum of 2 consecutive spectra with signal-
to-noise ratios .4 were included. The software employs a
probabilistic clustering algorithm and uses both isotopic distribu-
tion as well as conjugated masses for charge-state determination of
peptides/proteins. The resulting peak list characterizes each
polypeptide by its molecular mass, CE-migration time, and ion
signal intensity (amplitude) value. We applied a calibration method
for CE-migration time and ion signal intensity on the basis of
‘‘internal standard’’ peptides, which we proved to be superior over
creatinine normalization [29,30]. In addition, this method of
standardization is not affected by renal function, hence no
adjustments for reduced GFR are required [30] All detected
peptides were deposited, matched, and annotated in a Microsoft
SQL database, allowing further analysis and comparison of
multiple samples [31]. Peptides were considered identical within
different samples, when mass deviation was lower than 50 ppm for
small peptides or 75 ppm for larger peptides and proteins. Due to
analyte diffusion, CE peak widths increase with CE migration
time. In the data clustering process this effect was compensated by
linearly increasing cluster widths over the entire electropherogram
(19 to 45 min) from 2 to 5%. After calibration, deviation of
migration time was controlled to be below 0.45 min.
Establishment of stroke-specific classifiers
In order to develop the biomarker models that differed between
cases and controls, a random selection of 33 cases and 26 controls
was used. The remaining samples were then used to internally
validate the biomarker models. Biomarker models were generated
using the support-vector-machine (SVM) based MosaCluster
software [10,12]. The software generates multimarker models by
combination of polypeptides that are differentially distributed
between case and control samples. In SVM, a urine sample is
regarded as a p-dimensional vector, p being the number of
peptides included in the pattern. The SVM algorithm constructs a
(p21) –dimensional separation plane between case and control
vectors. From all possible hyperplanes that separate cases and
controls, the one with the largest distance to the nearest data
points on both sides is selected. Sample classification itself is
performed by determining the Euclidian distance of a particular
data set to the maximal margin of the hyperplane and assignment
of a positive or negative value depending on which side of the
hyperplane, case or control, the vector is located.
Urinary Proteomics and Stroke
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To develop a biomarker model related to stroke severity, the
normalized logarithmic amplitudes of significantly correlated
markers (nominal p-value ,0.01, r.0.33) were combined additive
in a linear model, as described [27].
Sequencing of peptides
The urine samples were analysed on a Dionex Ultimate 3000
RSLS nano flow system (Dionex, Camberly UK). The samples
(5 ml) were loaded onto a Dionex 100 mm62 cm 5 mm C18 nano
trap column at a flowrate of 5 ml/min by a Ultimate 3000 RS
autosampler (Dionex, Camberley UK) The composition of the
loading solution was 0.1% formic acid and acetonitrile (98:2).
Once loaded onto the trap column the sample was then washed off
into an Acclaim PepMap C18 nano column 75 mm615 cm, 2 mm
100 A˚ at a flowrate of 0.3 mm/min. The trap and nano flow
column were maintained at 35uC in a column oven in the
Ultimate 3000 RSLC. The samples were eluted with a gradient of
solvent A: 0.1% formic acid verses solvent B: acetonitrile starting
at 5% B rising to 50% B over 100 min. The column was washed
using 90% B before being equilibrated prior to the next sample
being loaded. The eluant from the column was directed to a
Proxeon nano spray ESI source (Thermo Fisher Hemel UK)
operating in positive ion mode then into an Orbitrap Velos
FTMS. The ionisation voltage was 2.5 kV and the capillary
temperature was 200uC. The mass spectrometer was operated in
MS/MS mode scanning from 380 to 2000 amu. The top 10
multiply charged ions were selected from each full scan for MS/
MS analysis, the fragmentation method was HCD at 35% collision
energy. The ions were selected for MS2 using a data dependant
method with a repeat count of 1 and repeat and exclusion time of
15 s. Precursor ions with a charge state of 1 were rejected. The
resolution of ions in MS1 was 60,000 and 7,500 for HCD MS2.
Data files from experiments performed on the HCD-enabled
LTQ were searched against the IPI rat non-redundant database
using the Open Mass Spectrometry Search Algorithm (OMSSA,
http://pubchem.ncbi.nlm.nih.gov/omssa) and SEQUEST (by
using Thermo Proteome Discoverer), without any enzyme
specificity. No fixed modification was selected, and oxidation of
methionine and proline were set as variable modifications. Mass
error window of 10 ppm and 0.05 Da were allowed for MS and
MS/MS, respectively. In the case of SEQUEST, the peptide data
were extracted using high peptide confidence and top one peptide
rank filters.
For further validation of obtained peptide identifications, the
strict correlation between peptide charge at pH of 2 and CE-
migration time was utilized to minimize false-positive identifica-
tion rates [32]: Calculated CE-migration time of the sequence
candidate based on its peptide sequence was compared to the
experimental migration time.
Statistical analysis
Descriptive statistics were used to describe the data. After testing
for normal distribution, continuous data were compared by
Wilcoxon t-test, as this test has proven to be of superior statistical
power in proteomics datasets [33]. A P-value ,0.05 was
considered to be statistically significant. P-values were calculated
using the natural-logarithm transformed intensities and the
Gaussian approximation to the t-distribution. In order to control
the false discovery rate, the scores were ranked and significance
thresholds were adjusted by the Benjamini and Hochberg method
[13]. Once candidate biomarker models were identified, their
sensitivity, specificity and area under the receiver operating
characteristic (ROC) curve were calculated. The relationship
between potential biomarkers and stroke severity measured by the
National Institute of Health Stroke Scale was compared using the
spearman correlation co-efficient.
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